In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria

PHASE4CompletedINTERVENTIONAL
Enrollment

452

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
MALARIA, FALCIPARUM
Interventions
DRUG

artemether-lumefantrine (AL)

Dispersible formulation of artemether-lumefantrine (Coartem-D™; 20mg artemether/120mg lumefantrine per tablet, Novartis, Switzerland) administered twice a day for 3 days according to manufacturer recommended dosing for weight

DRUG

artesunate-amodiaquine (ASAQ)

Co-formulated artesunate-amodiaquine (25mg artesunate/67.5mg amodiaquine and 50mg artesunate/135mg amodiaquine tablets) administered once a day for 3 days, according to manufacturer recommended dosing for weight

Trial Locations (1)

Unknown

Malaria Alert Center, University of Malawi College of Medicine, Blantyre, Malawi, Blantyre

All Listed Sponsors
collaborator

Kamuzu University of Health Sciences

OTHER

lead

Centers for Disease Control and Prevention

FED

NCT02637128 - In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria | Biotech Hunter | Biotech Hunter